Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.70 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 4/20 | 0.62 |
| ▸ | INSR | P06213 | 4/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.62 |
| ▸ | CDK2 | P24941 | 4/20 | 0.62 |
| ▸ | PLK1 | P53350 | 4/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2249292 | 0.99 | EGFR (0.69) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL2533904 | 0.88 | EGFR (0.70) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL16212746 | 0.87 | EGFR (0.69) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL29719074 | 0.87 | EGFR (0.69) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL22983584 | 0.85 | EGFR (0.67) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL29719131 | 0.85 | EGFR (0.67) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL14509726 | 0.85 | EGFR (0.75) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL2505296 | 0.85 | EGFR (0.77) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL2510931 | 0.85 | EGFR (0.75) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL233913 | 0.85 | EGFR (0.77) | EGFRERBB2GAKERBB4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-11 | — | — | US | disclosed |
| US-9102629-B2 | Polymorphic forms of 4-phenylamine quinazoline derivative, the preparation method and uses thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2015-08-11 | — | — | US | disclosed |
| US-20150133476-A1 | Polymorphic forms of 4-phenylamino quinazoline derivative, the preparation method and uses thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2015-05-14 | — | — | US | disclosed |
| US-8937079-B2 | Polymorph forms of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2015-01-20 | — | — | US | disclosed |
| WO-2014177038-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-11-06 | — | — | WO | disclosed |
| EP-2116540-B1 | P-TOLUENESULFONATE SALT OF A 4-ANILINE QUINAZOLINE DERIVATIVE | SHANGHAI ALLIST PHARMACEUTICALS INC (CN) | 2014-08-13 | — | — | EP | disclosed |
| EP-2269994-B1 | THE POLYMORPHS OF 4-ANILINOQUINAZOLINE DERIVATIVES, THE PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICALS INC (CN) | 2014-08-06 | — | — | EP | disclosed |
| US-20100168142-A1 | SALTS OF 4-ANILINE QUINAZOLINE DERIVATIVE | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2010-07-01 | — | — | US | disclosed |
| EP-2116540-A1 | THE SALTS OF 4-ANILINE QUINAZOLINE DERIVATIVE | SHANGHAI ALLIST PHARMACEUTICAL., INC. (CN) | 2009-11-11 | — | — | EP | disclosed |
| CN-101348466-A | Preparation of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)-anilino]-quinazoline-6-yl}-acrylamide | ALLIST PHARMACEUTICALS INC (CN) | 2009-01-21 | — | — | CN | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
| EP-1990337-A1 | QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICAL., INC. (CN) | 2008-11-12 | — | — | EP | disclosed |
| EP-1990337-A1 | QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICAL., INC. (CN) | 2008-11-12 | — | — | EP | disclosed |
| CN-101245050-A | 4-aniline quinazoline derivative salt | ALLIST PHARMACEUTICALS INC (CN) | 2008-08-20 | — | — | CN | disclosed |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133476-A1 | Polymorphic forms of 4-phenylamino quinazoline derivative, the preparation method and uses thereof | CYP2D6, ABCG2, CYP3A43 | EGFR 4165/4885ERBB2 3568/4885GAK 1795/4885 |
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | EGFR 677/4885ERBB2 691/4885GAK 612/4885 |
| US-20100168142-A1 | SALTS OF 4-ANILINE QUINAZOLINE DERIVATIVE | ACR, SLC6A4, TP53 | EGFR 1419/4885ERBB2 817/4885GAK 1880/4885 |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | WNK1, ABL1, NEK4 | EGFR 1223/4885ERBB2 368/4885GAK 205/4885 |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | GLS, GLS2, MCL1 | EGFR 677/4885ERBB2 691/4885GAK 612/4885 |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | EGFR 8/4885ERBB2 2/4885GAK 245/4885 |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | NQO2, AQP3, AQP1 | EGFR 2954/4885ERBB2 2993/4885GAK 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.